论文部分内容阅读
目的评价沙利度胺联合PF方案治疗晚期食管癌的疗效及毒副反应。方法 52例确诊晚期食管癌患者随机分为两组,试验组26例,对照组26例。每21 d为一周期,每两周期评价疗效。结果 52例均可评价疗效,试验组和对照组的有效率分别为57.7%和46.2%,两组差异无统计学意义(P>0.05);试验组中位疾病进展时间(TTP)5.9个月(3~7个月),中位生存期10.5个月;对照组中位疾病进展时间(TTP)4.1个月(3~6个月),中位生存期9.3个月。Karnofsky评分的改善率分别为76.9%和42.3%(P<0.05);试验组恶心、呕吐发生率较对照组低(P<0.05);试验组便秘、嗜睡以及乏力的发生率较对照组高(P<0.05)。其余二组之间比较差异均无显著性。两组病例均无化疗相关性死亡。结论试验组疗效优于对照组,明显减轻了毒副作用,不失为晚期食管癌患者的一种选择。
Objective To evaluate the efficacy and toxicity of thalidomide combined with PF regimen in the treatment of advanced esophageal cancer. Methods 52 patients diagnosed advanced esophageal cancer were randomly divided into two groups, the experimental group of 26 cases, control group of 26 cases. Every 21 days for a cycle, evaluation of the efficacy of every two cycles. Results All of the 52 cases could evaluate the curative effect. The effective rates of the experimental group and the control group were 57.7% and 46.2% respectively, with no significant difference between the two groups (P> 0.05). The median time to progression of disease (TTP) in the experimental group was 5.9 months (3-7 months). The median survival time was 10.5 months. The control group had a median time to progression (TTP) of 4.1 months (3-6 months) with a median survival of 9.3 months. The improvement rate of Karnofsky score was 76.9% and 42.3% respectively (P <0.05). The incidence of nausea and vomiting in the experimental group was lower than that in the control group (P <0.05). The incidences of constipation, lethargy and fatigue in the experimental group were higher than those in the control group P <0.05). The remaining two groups were no significant differences between the differences. There was no chemotherapy-related death in both groups. Conclusion The experimental group is better than the control group, significantly reducing the toxic side effects, after all, an option for patients with advanced esophageal cancer.